Learn More
INTRODUCTION Enzastaurin is an oral serine/threonine kinase inhibitor that targets protein kinase C-beta (PKC-β) and the phosphatidylinositol-3-kinase/AKT pathway. This trial assessed(More)
INTRODUCTION There is no consensus chemotherapy regimen with concurrent radiotherapy (RT) for inoperable stage IIIA/B non-small-cell lung cancer. This trial evaluated pemetrexed with carboplatin(More)
BACKGROUND Use of antiangiogenic agents in treatment of metastatic breast cancer (MBC) remains controversial. We evaluated the efficacy and safety of ramucirumab and eribulin versus eribulin alone as(More)
BACKGROUND Most alterations to chemotherapy dose and schedule are because of neutropenic events, which mainly occur in the first chemotherapy cycle. This prospective, community-based study evaluated(More)
18546 Background: Involuntary wt loss is a significant problem in pts with cancer and may lead to a decline in QOL, limit treatment options and reduce survival. Wt loss in these pts(More)
  • 1